Clark Estates Inc. NY Has $11.79 Million Position in Smith & Nephew SNATS, Inc. $SNN

Clark Estates Inc. NY lowered its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 51.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 325,000 shares of the medical equipment provider’s stock after selling 350,000 shares during the period. Smith & Nephew SNATS accounts for approximately 2.7% of Clark Estates Inc. NY’s portfolio, making the stock its 9th largest position. Clark Estates Inc. NY owned 0.08% of Smith & Nephew SNATS worth $11,794,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of SNN. Bank of Montreal Can lifted its holdings in Smith & Nephew SNATS by 321.6% in the second quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock valued at $105,056,000 after buying an additional 2,616,301 shares during the period. JPMorgan Chase & Co. raised its position in shares of Smith & Nephew SNATS by 6,663.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after acquiring an additional 1,192,755 shares in the last quarter. ABC Arbitrage SA lifted its stake in shares of Smith & Nephew SNATS by 1,063.4% in the 2nd quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider’s stock valued at $27,525,000 after purchasing an additional 821,393 shares during the period. Todd Asset Management LLC acquired a new stake in Smith & Nephew SNATS during the third quarter worth approximately $26,319,000. Finally, Goldman Sachs Group Inc. increased its holdings in Smith & Nephew SNATS by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock worth $50,255,000 after purchasing an additional 583,809 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wall Street Zen cut Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group dropped their target price on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday, November 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Kepler Capital Markets upgraded shares of Smith & Nephew SNATS to a “strong-buy” rating in a report on Monday, November 17th. Finally, Royal Bank Of Canada cut shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Smith & Nephew SNATS presently has an average rating of “Hold” and an average target price of $35.75.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock opened at $36.10 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00. The firm has a fifty day simple moving average of $33.77 and a two-hundred day simple moving average of $34.94. Smith & Nephew SNATS, Inc. has a 12 month low of $23.91 and a 12 month high of $38.79.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.